Embecta Corp. — Q2 FY2024 Form 10-Q
Reporting period: Three and six months ended March 31, 2024. Embecta is a global diabetes-care medical device company selling pen needles, syringes, safety devices and related products. Amounts below are in millions of dollars except per-share data.
Financial performance
| Metric | Q2 FY2024 | Q2 FY2023 | Six months FY2024 | Six months FY2023 |
|---|---|---|---|---|
| Revenue | $287.2 | $277.1 | $564.5 | $552.8 |
| Gross profit | $185.4 | $189.8 | $371.3 | $378.6 |
| Gross margin | 64.6% | 68.5% | 65.8% | 68.5% |
| Operating income | $39.2 | $55.6 | $84.7 | $144.4 |
| Net income | $28.9 | $14.0 | $49.0 | $49.2 |
| Diluted EPS | $0.50 | $0.24 | $0.85 | $0.85 |
- Q2 revenue rose 3.6%, driven by $15.0 of favorable volume, partly offset by foreign exchange, lower pricing and reduced contract manufacturing revenue. Six-month revenue increased 2.1%.
- Cost of products sold rose 16.6% in Q2 and 10.9% for the half year. Management cited inflation in materials, freight, labor and overhead; unfavorable manufacturing variances, including a planned Suzhou facility shutdown; and foreign exchange. Gross margin contracted accordingly.
- Operating income declined 29.5% in Q2 and 41.3% for the first half. Higher selling and administrative and separation-related costs contributed; research and development expense declined year over year for the half.
- Net income was higher in Q2 despite lower operating income, largely reflecting a tax benefit. The six-month effective tax rate was negative 102.5%, including an approximately $18.8 tax benefit related to prior-year Swiss withholding taxes and an approximately $17.1 benefit from establishing a Swiss deferred tax asset. These items make reported earnings less indicative of underlying operating performance.
Cash, debt and liquidity
- Cash and restricted cash totaled $306.5 at March 31, 2024, down $20.0 from September 30, 2023. Six-month operating cash flow was $11.2, compared with $47.4 a year earlier; capital expenditures were $6.1, dividends paid were $17.2, and debt repayments were $4.8.
- Trade receivables increased to $123.7 from $16.7 at September 30, 2023. Management attributed the increase primarily to Embecta taking over collection of receivables as factoring arrangements with BD ended, and expects to collect outstanding amounts during fiscal 2024 in line with customer payment terms.
- Principal debt was $1,631.0: $931.0 on the Term Loan and $700.0 of senior secured notes. Reported long-term debt was $1,591.8; weighted-average debt cost was 7.1%. The $500.0 revolving facility was undrawn. The company reported covenant compliance.
- Management said cash, operating cash flow and revolving capacity should provide sufficient flexibility for foreseeable needs, including working capital, debt service and dividends. A 100-basis-point rate change would affect Term Loan interest expense by approximately $9.3 annually, based on the period-end balance.
Material developments, outlook and risks
- Separation and stand-up costs were $32.6 in Q2 and $59.0 for the six months, versus $25.6 and $35.5 in the comparable periods. The company expects similar costs to continue in the current year as it establishes standalone functions and implements its ERP system.
- BD extended certain transition and logistics services in a limited set of markets through November 1, 2024. Factoring agreements with BD had expired by March 31. Embecta continues to rely on some BD processes and financial controls in China, Taiwan, India and certain Latin American countries.
- The ERP system went live in North America in November 2023 and in EMEA and Greater Asia in March 2024. Management described supply-chain inflation and disruption, but said it had maintained uninterrupted customer supply through higher inventory and other measures.
- Embecta submitted its first FDA 510(k) filing for its proprietary disposable insulin delivery system in December 2023. The filing provides no specific financial guidance or quantified forecast for the product.
- Key disclosed risks include pricing pressure and commoditization, shifts toward alternative diabetes therapies and insulin pumps, raw-material and freight costs, interest-rate and foreign-exchange exposure, dependence on BD transition services and supply arrangements, and geopolitical or trade disruption. Management reported no material operational or financial impact from the conflicts it was monitoring as of May 9, 2024, while noting future effects remain uncertain.
- The company reported no material legal proceedings. Three customers represented about 42% of gross revenue in the quarter and half year; four customers represented about 63.6% of trade receivables at period end.
Important facts for investors to verify
- Whether the elevated receivables convert to cash as management expects, and how working-capital cash flow develops after the transition away from BD factoring.
- What drove the increase in the variable-consideration liability to $177.2 from $36.4 at September 30, 2023, and whether rebate and other sales-deduction estimates change materially. Q2 sales deductions were $138.5 versus $95.2 a year earlier.
- Progress and costs of ERP and standalone-process implementation, including the November 1, 2024 end date for extended BD services and the remaining reliance on BD controls in some markets.
- Whether margin pressure, separation costs and variable-rate debt constrain cash generation, dividends or covenant headroom.
- The timing and outcome of FDA review for the disposable insulin delivery system and the commercial prospects of the planned product.